8 results about "Molecular virology" patented technology

This invention belongs to the fields of molecular virology and immunology, and provides an alpaca-derived nanobody that specifically binds to Chikungunya virus (CHIKV), its preparation method, and its applications. The nanobody has a heavy chain variable region (VHH), which comprises the following CDRs: CDR1 (amino acid sequence as shown in SEQ ID NO:1), CDR2 (amino acid sequence as shown in SEQ ID NO:2), and CDR3 (amino acid sequence as shown in SEQ ID NO:3). The VHH includes four frame regions FR1-FR4; FR1, FR2, FR3, and FR4 are arranged alternately with CDR1, CDR2, and CDR3 in sequence. The nanobody of this invention can efficiently neutralize CHIKV virus and inhibit its infection, and has the potential to prepare drugs or kits for the prevention, treatment, and / or detection of CHIKV infection. The nanobody of this invention can bind with high affinity to the E protein of CHIKV, effectively inhibiting CHIKV pseudovirus infection.

The invention discloses a monoclonal antibody of Japanese encephalitis virus and Zika virus and application of the monoclonal antibody, and belongs to the technical field of immunology and molecular virology. The monoclonal antibody or the antigen binding fragment thereof comprises VH CDR1, VH CDR2 and VH CDR3 of which the amino acid sequences are shown as SEQ ID NO: 1-3, and VL CDR1 and VL CDR3 of which the amino acid sequences are shown as SEQ ID NO: 4 and SEQ ID NO: 5, and the amino acid sequence is VL CDR2 of AAS. The monoclonal antibody LZY2086 provided by the invention can be combined with E protein extracellular regions of the encephalitis B virus and the Zika virus with high affinity, and has very strong neutralizing activity on the encephalitis B virus and the Zika virus. Therefore, as a broad-spectrum neutralizing antibody, the monoclonal antibody LZY2086 disclosed by the invention has ideal clinical application value in prevention and treatment of Japanese encephalitis virus and Zika virus infection.

The invention relates to neurobiology, molecular virology, biomedical engineering and the like, and discloses a domesticated low-serum Vero cell line and a method for preparing an HSV virus vector through suspension culture cell amplification. Aiming at the bottleneck problem that a process for amplifying HSV by adherent culture of Vero cells is difficult to realize large-scale and engineering amplified production, the invention researches and develops a method for preparing HSV based on suspension culture of cell amplification. Vero cells introduced from ATCC are domesticated, and the serum content of a culture medium is gradually reduced, so that the Vero cells are suitable for suspension culture in a microcarrier or sheet carrier reactor by using a low-serum or serum-free culture medium. The method comprises the following steps: using Tamp of Dibide Bioengineering (Shanghai) Co., Ltd; and carrying out suspension culture of the Vero cells and infection amplification of the HSV virus vector by using a J Cloud Ready TM bioreactor. High-activity suspension culture and HSV amplification of Vero cells are realized by optimizing production conditions, cell density, biochemical detection and the like, and a stable and efficient method is provided for preparing a high-titer and high-purity HSV virus vector in combination with purification process upgrading.

The present invention relates to the field of immunology and molecular virology, in particular the field of prevention and treatment of RSV. In particular, the present invention provides monoclonal antibodies capable of specifically binding to a new epitope between the pre-F protein and the V epitope or a new epitope between the II and the V epitope, and their use for the detection, prevention and / or treatment of RSV infection and / or diseases caused by said infection.

The present invention relates to the field of immunology and the field of molecular virology, in particular the field of diagnosis, prevention and treatment of SARS-CoV-2. In particular, the present invention relates to monoclonal antibodies against SARS-CoV-2, and compositions (e.g., diagnostic and therapeutic agents) comprising said antibodies. Furthermore, the present invention also relates to uses of said antibodies. The antibodies of the present invention can be used for the diagnosis, prevention and / or treatment of SARS-CoV-2 infection and / or a disease caused by said infection (e.g., COVID-19).

The present disclosure relates to the field of molecular virology, including nucleic acid molecules comprising modified viral genomes or self-replicating RNA, pharmaceutical compositions comprising the same, and the use of such nucleic acid molecules and compositions to produce desired products in cell culture or in an organism. Methods for inducing a pharmacodynamic effect in a subject in need thereof, as well as methods for preventing and / or treating various health conditions, are also provided.

The invention discloses a herpes simplex virus HSV1 MacIntyre recombinant virus, a cross-multilevel synaptic neural circuit tracing tool and application, and relates to neurobiology, molecular virology and the like. The recombinant herpes simplex virus is constructed based on a herpes simplex virus HSV-1 MacIntyre clinical strain virus, a US9 gene of the virus is knocked out through genetic modification, and an exogenous fluorescent gene expression cassette is inserted into a gene locus to construct the recombinant virus. A clinical strain virus is constructed into a novel visual tool virus vector by modifying an HSV1 MacIntyre genome and inserting a fluorescent protein gene or other exogenous genes. Animal marker experiments show that when the HSVMac tracer virus is injected into a specific brain region of a mouse, the characteristic of reverse transsynaptic propagation is shown, and efficient reverse tracing or exogenous gene delivery expression of a cross-species animal neural circuit marker can be realized; the problem that non-human primate brain neural circuit reverse trans-synaptic tracing lacks tracing technology and tool in the fields of brain atlas drawing and neural circuit tracing is solved.

The present invention relates to the field of immunology and the field of molecular virology, in particular the field of diagnosis, prevention and treatment of coronaviruses, such as SARS-CoV-2 and / or SARS-CoV-1. In particular, the present invention relates to monoclonal antibodies against coronaviruses, as well as compositions comprising said antibodies, e.g. diagnostic and therapeutic agents. Furthermore, the present invention also relates to uses of said antibodies. The antibodies of the present invention can be used for the diagnosis, prevention and / or treatment of a coronavirus infection and / or a disease caused by said infection.